The national rollout of the maternal vaccination initiative in Scotland and the nirsevimab immunisation programme in Tarragona, Spain, have successfully reduced infant hospitalisations from respiratory syncytial virus by more than 80 percent, according to real-world data published in The Lancet Infectious Diseases.
While infections frequently present as a mild upper respiratory illness resembling a common cold, the pathogen can rapidly trigger severe lower respiratory tract disease, including bronchiolitis and pneumonia, in infants under six months of age and those born prematurely.
In Plain English: The Clinical Takeaway
- Protective Antibodies: Maternal vaccination prompts the pregnant person to generate antibodies that cross the placenta, shielding the newborn during their most vulnerable months.
- Timing is Critical: Infants born less than 14 days after maternal vaccination do not acquire adequate passive immunity because the biological transfer requires time.
- Real-World Efficacy: Population-wide data confirms that preventative immunisation cuts severe hospital admissions by over 80 percent, alleviating winter pressures on acute pediatric care.
Real-World Evidence from National Rollouts
Recent epidemiological evaluations from Scotland, published in The Lancet Infectious Diseases, mark the first time maternal RSV immunisation has been assessed across an entire national population. Researchers from Public Health Scotland, alongside a multidisciplinary team including Professor Sir Aziz Sheikh from the Nuffield Department of Primary Care Health Sciences, evaluated health outcomes for all 27,552 infants born in Scotland between August 2024 and March 2025. During this inaugural season, approximately half of all pregnant women accepted the vaccine, which is recommended starting at 28 weeks gestation.
The findings demonstrated that timely maternal immunisation prevented hundreds of hospital admissions. However, data underscored a strict biological window: infants born less than 14 days following maternal inoculation did not receive meaningful protection. This delay occurs because the maternal immune system requires sufficient time to mount an antibody response and transfer those immunoglobulins across the placental barrier.
Parallel real-world evaluations examining the nirsevimab monoclonal antibody rollout in Tarragona, Spain, similarly demonstrated an 80 percent reduction in infant RSV hospitalisations. Globally, RSV accounts for an estimated 3.6 million hospital admissions annually among young children, making these population-wide reductions a major milestone for public health.
| Region / Study Site | Intervention Type | Target Population | Observed Reduction in Hospitalisation |
|---|---|---|---|
| Scotland (National Study) | Maternal RSV Vaccine (from 28 weeks) | 27,552 Infants (Aug 2024–Mar 2025) | Significant prevention of hundreds of admissions (First national rollout) |
| Tarragona, Spain | Nirsevimab Monoclonal Antibody | Infants / Neonates | Greater than 80% reduction |
Commenting on the broader public health impact, Professor Sir Aziz Sheikh noted: These results show, on a national scale and using real-world data, that maternal RSV vaccination is making a substantial difference to the health of young babies. In its first season alone, the programme prevented hundreds of hospital admissions, sparing families significant distress and reducing winter pressures on the NHS. This is compelling evidence that rolling out maternal RSV vaccination globally could save many lives.
Dr Ross McQueenie, Lead Healthcare Scientist for Vaccine Effectiveness and Respiratory Inequalities at Public Health Scotland, added: The early success of the maternal RSV vaccine illustrates the preventative value of public health immunisation programmes. This vaccination, like so many others, stops serious illness and improves the health of children and communities.
Contraindications & When to Consult a Doctor
References
- Public Health Scotland & University of Oxford. (2025). Maternal RSV vaccine prevents hundreds of infant hospitalisations in first real-world national study. The Lancet Infectious Diseases.
Disclaimer: This article is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional regarding any questions about vaccination or infant health conditions.
